These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 39122738)

  • 1. Factors associated with incomplete tuberculosis preventive treatment: a retrospective analysis of six-years programmatic data in Cambodia.
    An Y; Khun KE
    Sci Rep; 2024 Aug; 14(1):18458. PubMed ID: 39122738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tuberculosis preventive treatment uptake among people living with HIV during COVID-19 period in Addis Ababa, Ethiopia: a retrospective data review.
    Gebreegziabher SB; Ashuro AA; Kumssa TH; Teferi MY; Alemayue EA; Datiko DG; Yimer SA; Shagre MB
    BMC Infect Dis; 2024 May; 24(1):499. PubMed ID: 38760665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to preventive treatment for latent tuberculosis infection in close contacts of pulmonary tuberculosis patients: A cluster-randomized controlled trial in China.
    Chen H; Zhang H; Cheng J; Sun D; Wang Q; Wu C; Liu Y; Xia Y; Xu C; Zhang C
    Int J Infect Dis; 2024 Oct; 147():107196. PubMed ID: 39074738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuberculosis Preventive Treatment.
    Tayal A; Kabra SK
    Indian J Pediatr; 2024 Aug; 91(8):823-829. PubMed ID: 38095783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
    Doan TN; Fox GJ; Meehan MT; Scott N; Ragonnet R; Viney K; Trauer JM; McBryde ES
    J Antimicrob Chemother; 2019 Jan; 74(1):218-227. PubMed ID: 30295760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study.
    Schein YL; Madebo T; Andersen HE; Arnesen TM; Dyrhol-Riise AM; Tveiten H; White RA; Winje BA
    BMC Infect Dis; 2018 Nov; 18(1):587. PubMed ID: 30453946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda.
    Sensalire S; Karungi Karamagi Nkolo E; Nabwire J; Lawino A; Kiragga D; Muhire M; Kadama H; Katureebe C; Namuwenge P; Musinguzi J; Calnan J; Seyoum D
    AIDS Res Ther; 2020 May; 17(1):28. PubMed ID: 32460788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher Completion Rates With Self-administered Once-weekly Isoniazid-rifapentine Versus Daily Rifampin in Adults With Latent Tuberculosis.
    Haas MK; Aiona K; Erlandson KM; Belknap RW
    Clin Infect Dis; 2021 Nov; 73(9):e3459-e3467. PubMed ID: 32915203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.
    Sandul AL; Nwana N; Holcombe JM; Lobato MN; Marks S; Webb R; Wang SH; Stewart B; Griffin P; Hunt G; Shah N; Marco A; Patil N; Mukasa L; Moro RN; Jereb J; Mase S; Chorba T; Bamrah-Morris S; Ho CS
    Clin Infect Dis; 2017 Oct; 65(7):1085-1093. PubMed ID: 28575208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementing 3HP vs. IPT as TB preventive treatment in Pakistan.
    Jaswal M; Farooq S; Madhani F; Noorani S; Salahuddin N; Amanullah F; Khowaja S; Safdar N; Khan A; Yuen C; Keshavjee S; Becerra M; Hussain H; Malik AA
    Int J Tuberc Lung Dis; 2022 Aug; 26(8):741-746. PubMed ID: 35898140
    [No Abstract]   [Full Text] [Related]  

  • 11. Scale-Up of Rifapentine and Isoniazid for Tuberculosis Prevention Among Household Contacts in 2 Urban Centers: An Effectiveness Assessment.
    Hussain H; Jaswal M; Farooq S; Safdar N; Madhani F; Noorani S; Shahbaz SS; Salahuddin N; Amanullah F; Khowaja S; Manzar S; Shah JA; Islam Z; Dahri AA; Shahzad M; Keshavjee S; Becerra MC; Khan AJ; Malik AA
    Clin Infect Dis; 2023 Aug; 77(4):638-644. PubMed ID: 37083926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.
    Sun HY; Huang YW; Huang WC; Chang LY; Chan PC; Chuang YC; Ruan SY; Wang JY; Wang JT
    Tuberculosis (Edinb); 2018 Jul; 111():121-126. PubMed ID: 30029896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study.
    Surey J; Stagg HR; Yates TA; Lipman M; White PJ; Charlett A; Muñoz L; Gosce L; Rangaka MX; Francis M; Hack V; Kunst H; Abubakar I
    BMC Infect Dis; 2021 Jan; 21(1):90. PubMed ID: 33478428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.
    Walker RE; Bass S; Srinivas P; Miranda C; Johnson L; Pallotta AM
    Ann Pharmacother; 2020 May; 54(5):457-463. PubMed ID: 31729245
    [No Abstract]   [Full Text] [Related]  

  • 15. Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study.
    Lam CK; McGinnis Pilote K; Haque A; Burzynski J; Chuck C; Macaraig M
    J Med Internet Res; 2018 Nov; 20(11):e287. PubMed ID: 30459146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine.
    McClintock AH; Eastment M; McKinney CM; Pitney CL; Narita M; Park DR; Dhanireddy S; Molnar A
    BMC Infect Dis; 2017 Feb; 17(1):146. PubMed ID: 28196479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial.
    Semitala FC; Kadota JL; Musinguzi A; Nabunje J; Welishe F; Nakitende A; Akello L; Bishop O; Patel D; Sammann A; Nahid P; Belknap R; Kamya MR; Handley MA; Phillips PPJ; Katahoire A; Berger CA; Kiwanuka N; Katamba A; Dowdy DW; Cattamanchi A
    PLoS Med; 2021 Dec; 18(12):e1003875. PubMed ID: 34914696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementation of tuberculosis preventive therapy with INH-Rifapentine (3HP) for latent tuberculosis infection management in household tuberculosis contacts in India: A prospective study.
    Sharma N; Bakshi R; Basu S; Zode M; Arora R; Khanna A
    Trop Med Int Health; 2023 Dec; 28(12):890-900. PubMed ID: 37864386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting.
    Yuen CM; Majidulla A; Jaswal M; Safdar N; Malik AA; Khan AJ; Becerra MC; Keshavjee S; Lu C; Hussain H
    Clin Infect Dis; 2021 Sep; 73(5):e1135-e1141. PubMed ID: 33289039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved treatment completion with shorter treatment regimens for latent tuberculous infection.
    Macaraig MM; Jalees M; Lam C; Burzynski J
    Int J Tuberc Lung Dis; 2018 Nov; 22(11):1344-1349. PubMed ID: 30355415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.